Extended interval between enzyme therapy infusions for adult patients with Gaucher's disease type 1

Journal of Postgraduate Medicine

Volumn 49, Issue 2, 2003, Pages 127-130

  Pérez Calvo, Juan ^e   Giraldo, P ^a   Pastores, G M ^b   Fernandez Galan M ^c   Martin Nunez G ^c   Pocovi M ^d  

^a HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HOSPITAL VIRGEN DEL PUERTO   (Spain)

^d UNIVERSITY OF ZARAGOZA   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Alglucerase; Enzyme replacement therapy; Gaucher's disease; Imiglucerase

Indexed keywords

ALGLUCERASE; GLUCOSYLCERAMIDASE; IMIGLUCERASE;

ADULT; ANEMIA; ARTICLE; BONE MARROW; CASE REPORT; CELL INFILTRATION; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; HUMAN; LIVER SIZE; MALE; SPLEEN SIZE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; TIME FACTORS;

EID: 17044440923     PISSN: 00223859     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency macrophage-targeted glucocerebrosidase for Gaucher's disease N Engl J Med 1991;324:1464-70.
2. Figueroa ML, Rosenbloom BE, Kay AC, Garver P, Thurston DW, Koziol JA, et al. A less costly regimen of alglucerase to treat Gaucher's disease. N Engl J Med 1992;327:1632-6.
3. Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A. Withdrawal of enzyme replacement therapy in Gaucher's disease. Br J Haematol 2000;110:488-92.
4. Brady RO, Barton, NW. Enzyme replacement therapy for Gaucher disease, critical investigations beyond demonstration of clinical efficacy. Biochem Med Metab Biol 1994;52:1-9.
5. Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1, dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 1993;82:408-16.
6. Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher disease, the first 5 years. Blood Rev 1998;12:115-33.
7. Giraldo P, Pocoví M, Perez-Calvo J, Rubio-Felix D, Giralt M. Report of the Spanish Gaucher's disease registry, clinical and genetic characteristics. Haematologica 2000;85:792-9.
8. Hollak CE, Corssmit EP, Aerts JM, Endert E, Sauerwein HP, Romijn JA, et al. Differential effects of enzyme supplementation therapy on manifestations of type 1 Gaucher disease. Am J Med 1997;103: 185-91.
9. Altarescu G, Schiffmann R, Parker CC, Moore DF, Kreps C, Brady RO, et al. Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis 2000;26:285-90.
10. Beutler E, Kay A, Saven A, Garver P, Thurston D, Dawson A, et al. Enzyme replacement therapy for Gaucher disease. Blood 1991;78:1183-9.
11. Zaizov R, Frisch A, Cohen IJ. Lower-dose, high-frequency enzyme replacement therapy in children with type 1 Gaucher disease, Experience at the Schneider Children's Medical Center of Israel. Semin Hematol 1995;32(Suppl 1):39-44.
12. Migita M, Fukunaga Y, Ueda T, Watanabe A, Morita T, Yamamoto M. Progression of bone disease without deterioration of haematological parameters in a child with Gaucher disease during low-dose glucocerebrosidase therapy. Nippon Ika Daigaku Zasshi 1994;61:633-7.
13. Mistry PK, Davies S, Corfield A, Dixon AK, Cox TM. Succesful treatment of bone marrow failure in Gaucher's disease with low-dose modified glucocerebrosidase. Q J Med 1992;84:541-6.
14. Czartoryska B, Tylki-Szymanska A, Lugowska A. Changes in serum chitotriosidase activity with cessation of replacement enzyme (cerebrosidase) administration in Gaucher disease. Clin Biochem 2000;33:147-9.
15. Grinzaid KA, Geller E, Hanna SL, Elsas LJ 2nd. Cessation of enzyme replacement therapy in Gaucher disease. Genet Med 2002;4: 427-33.